Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

URMC rheumatologist presents data showing drug’s potential to ease arthritis symptoms
Therapeutic class review, Neurological - multiple sclerosis dalfampridine (Ampyra(TM))
Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy.
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
Integrated analysis of daclizumab HYP pharmacokinetics from three phase 1 studies
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
Role of the Blood-Brain Barrier in Multiple Sclerosis.
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.
Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
Imaging robust microglial activation after lipopolysaccharide administration in humans with PET.
Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases.
Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
Optimizing IFN Beta - 1B Dose (Optims)
Estimating Time to Disease Progression Comparing Transition Models and Survival Methods-An Analysis of Multiple Sclerosis Data.
GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications
Ofatumumab
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
Genetics of multiple sclerosis: swimming in an ocean of data.

Pages